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ABSTRACT
Lymphatic Filariasis (elephantiasis) is a neglected tropical disease caused by the 
filarial nematodes Brugia malayi (B. malayi), Brugia timori, and Wuchererici Bancrofti 
(1,8). These parasites are present in over 83 counties in the tropics and sub-tropics where 
more than 1.4 billion people are at risk of infection and 130 million people are presently 
infected (1,7). Previous work from our lab has led to the identification and expression of 
a B. malayi stress-activated protein kinase, Bm-MPKl (a human p38/C. elegans PMK-1 
ortholog). Bm-MPKl plays an important role in the parasites’ protection against 
oxidative stress (1), and as such is a potential therapeutic drug target for the treatment of 
Lymphatic Filariasis. Bm-MPKl was successfully expressed in mammalian HEK-293 F 
cells yielding levels suitable for characterization of the enzyme. However, these cells did 
not produce adequate levels of recombinant protein for crystallography and high 
throughput screening purposes. In order to produce high levels of recombinant Bm- 
MPKl, I have established a novel SF9 cell/Baculovirus expression system. A synthetic 
Bm-MPKl was successfully subcloned into a pFASTBAC plasmid, which was then 
transposed into DHlOBac cells to generate a Bm-MPKl/pFASTBAC-based baculovirus. 
Using this system, I have demonstrated that recombinant Bm-MPKl protein kinase is 
highly expressed in infected SF9 insect cells. Similar to mammalian cell expression, I 
demonstrated that Bm-MPKl can be activated in SF9 infected cells by treatment with 
sodium arsenate. An excellent yield of recombinant Bm-MPKl was obtained with 
approximately 3.25 mg of protein recovered from a 100 mL culture.
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INTRODUCTION
Lymphatic Filariasis (elephantiasis) is an infectious disease caused by thread­
like nematode worms, Brugia malayi (B. malayi), Brugia timori, and Wuchereria 
Bancrofti (1,6). These parasites are endemic in over 83 countries in the tropics and sub­
tropics where more than 1.4 billion people are at risk of infection and approximately 130 
million people are currently infected (6). Elephantiasis has a major impact on society 
because it leads to long-term and permanent disability (6, 7, 8). The life cycle of the 
filarial parasites has three different stages: microfilaria (mf), infective larva (La or L3) 
and adults. B. malayi parasites are transmitted by the Mansonia species of mosquito (6). 
The cycle begins when a mosquito takes a blood meal from an infected person and 
ingests mfs, which subsequently develop into L3 infectious larvae in the mosquito. 
When the infected mosquitos take another blood meal, they introduce L3 into the host. 
L3s molt and develop into L4 larvae, which migrate to the lymphatic vessels and develop 
into adult worms. Adult worms can live from 8-15 years in the lymphatic system of the 
host (6). During this time, adult female worms produce millions of mfs, which are 
introduced into the blood stream living up to 14-70 days (9).
The current drugs used to treat lymphatic filariasis are diethylcarbamazine 
citrate (DEC), albendazole, and Ivermectin. These drugs can effectively remove 99% of 
mf from the blood; however, they fail to kill adult worms (9). To interrupt filarial 
transmission quickly and to eliminate the disease, it is necessary to find new therapeutic 
drug targets that kill both mf and adult worms. The sequencing of the B. malayi genome
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should help to provide a better understanding of filarial parasite biology and potential 
drug targets.
Recent studies in our lab have led to the identification of a potential drug target 
in B. malayi. A B. malayi p38/PMK-l ortholog, Bm-MPKl, was identified and shown to 
be critical for protective responses against reactive oxygen species (ROS) produced by 
macrophages, neutrophils, eosinophils, and basophil granulocytes during infection (1). 
ROS promotes protein modification, lipid oxidation, and nucleic acid damage (1). 
Human stress activated protein kinase p38, PMK-1 from C. elegans, and the Bm-MPKl 
are members of the mitogen-activated protein kinase (MAPK) superfamily. They exhibit 
the characteristic 12-domain protein structure as well as the highly conserved TGY 
activation-motif in domain VIII (1, 13).
MAP kinases play an important role in cellular responses to external stress 
signals including osmotic stress, viral infection, UV, heat, and inflammatory cytokines 
(1, 2). In humans, p38 is activated via dual phosphorylation of TGY motif by the 
upstream kinases, MKK3 and MKK6 (13). This results in conformational changes, 
which modifies the configuration of N-terminal and C-terminal domains leading to an 
increased interaction with substrate that enhances enzymatic activity (13). Activated p38 
leads to the phosphorylation and activation of a variety of protein kinases and 
transcription factors (1, 13). In addition, PMK-1 found in free-living nematode C. 
elegans, is similarly activated by dual phosphorylation of TGY motif by an upstream 
kinase SEK-1. The activation of PMK-1 leads to the phosphorylation of a transcription
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factor, SKN-1 resulting in translocation of SKN-1 into intestinal nuclei where it regulates 
the expression of a variety of antioxidant and phase II detoxification genes (1). It has 
been shown that the filarial parasite B. malayi has a similar stress-activated signaling 
pathway where Bm-MPKl is activated by dual phosphorylation of an upstream kinase, 
Bm-SEK-1; however, the downstream kinase SKN-1 is absent in B. malayi. We believe 
that activation of Bm-MPKl plays a similar role in activating various transcription 
factors.
It has been previously demonstrated in our lab that known p3 8 inhibitors inhibit 
Bm-MPKl and compromise the ability of B. malayi to counteract oxidative stress 
validating Bm-MPKl as a potential anti-parasitic target. To that end, the Celgene 
Corporation is currently sponsoring a drug discovery effort in our lab. In order to screen 
large numbers of protein kinase inhibitors for activity against Bm-MPKl and to generate 
enough Bm-MPKl for determining a crystal structure for the kinase, large quantities of 
Bm-MPKl are required. To support the efforts, a highly efficient expression system is 
required for the production of recombinant enzyme. MAP kinases produced in bacterial 
systems are usually inactive because they are not phosphorylated at their specific 
activating threonine and tyrosine residues (3). Expression of MAP kinases in mammalian 
systems such as human embryonic kidney cells (HEK 293T & HEK 293F) has the 
advantage that the kinases can be activated by stressing the cells with sodium arsenate (1, 
3). Although mammalian expression systems produce enough recombinant Bm-MPKl 
for studying this enzyme at the biochemical level, they are not adequate for producing 
high level of recombinant proteins for high throughput screening.
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In order to increase the production of recombinant, active, Bm-MPKl, I 
established the SF9 cell/Baculovirus expression system in the lab. The SF9 
cell/Baculovirus expression system is widely used to express heterogeneous genes in 
cultured insect cells and yields high-level protein expression (13). Baculoviruses are 
double-stranded, circular, supercoiled DNA molecules in a rod-shaped capsid originating 
from arthropods (12). The two most common isolates used for foreign gene expression 
are known as AcMNPV (Autographa californica multiple nuclear polyhedrosis virus) and 
BmNPV {Bombyx mori (silkworm) nuclear polyhedrosis virus). The virus replication 
occurs in three stages [Early phase (virus synthesis phase), Late phase (viral structural 
phase), and Very Late phase (viral occlusion protein phase)] leading to both lytic and 
occluded life cycles.
SF9 cells are a clonal isolate of the Spodoptera frugiperda cell line IPLB-Sf21- 
AE, and are extensively used for Baculovirus Expression Vector Systems (BEVS). These 
cells were originally derived from ovarian tissue of the fall armyworm (12). The 
polyhedrin gene within the wild-type viral genome can be replaced with an exogeneous 
open reading frame, allowing a recombinant baculovirus to be used as an expression 
vector for vitro infection of insect cells. The recombinant genes are placed under the 
transcriptional control of the strong polyhedrin promoter, which is active during the very 
late stage of infection. Thus, recombinant product is expressed in place of the naturally 
occurring polyhedrin protein. When SF9 cells are infected with recombinant baculovirus, 
cellular structure begins to change in the early phase (30 min -6 h) of infection. Normal 
cellular functions decline and early-phase viral proteins become evident. Normal cellular
4
functions terminate in the late phase (6 h-24 h) of infection. At this point cells stop 
dividing and budding virus production increases dramatically. During the very late stage 
of infection (20- 36 h after infection), budding virus production stops and the assembly, 
production, and expression of recombinant gene product begins.
The SF9 cells/Baculovirus system is a very useful eukaryotic protein expression 
system for recombinant protein expression, with the advantages of biological safety, ease 
of scale up, high levels of recombinant gene expression and the full complement of 
eukaryotic posttranslational modifications. The main goal of my project was to develop 
the SF9 cells/Baculovirus protein expression system for the high-level production of 
parasitic protein kinases for high-level inhibitor screening and crystallization studies.
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MATERIALS & METHODS
I. Generation of a pFASTBAC plasmid containing a Bm-MPKl insert
The SF9Bm-MPKl gene (Figure 1) was chemically synthesized and cloned into 
pUC57 vector (Genscript, Piscataway, NJ). The SF9Bm-MPKl gene was excised from 
pUC57 and sub-cloned into Vector “S”, a modified pFASTBAC plasmid containing an 
N-terminal GST-tag and two different Sfil sites flanking the open reading frame to be 
expressed. Vectors of this kind allow the easy parallel expression evaluation of ORFs 
(open reading frames) as well as easy transfer of DNA sequences into proper vectors for 
different expression hosts with a single subcloning step. The SF9Bm-MPKl gene is 
flanked by the Sfil site A (5’-GGCCtcagcGGCC-3’) on its 5’ end and by the Sfil B site 
(5’- GGCCgggtcGGCC-3’) on its 3’-end, allowing easy, directional subcloning with only 
one restriction cut.
The lyophilized pUC57/SF9Bm-MPKl plasmid was reconstituted in water (80 
pg/pl) as per manufacturer’s instructions (Genscript). The pUC57/SF9Bm-MPKl 
plasmid (2 pg) and Vector “S” were digested in a 50 pi volume with 2 pi of Sfil 
restriction enzyme (10 units/pl) and 5 pi of 10X Sure/Cut Buffer M for Restriction 
Enzyme (Roche Molecular Biochemicals, RMB). The reaction was incubated in a 50°C 
water bath for 90 min. The digested plasmids were loaded onto a 1.5% agarose gel in lx 
TAE buffer along with kHindIII0X Haelll DNA marker (310-23,130 base pairs) to 
obtain a Bm-MPKl/sfl1 insert and Vector S/sfiI fragment. The bands were excised with a
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sterile razor blade and purified using the QIAquick gel extraction kit protocol 
(QIAGEN).
The purified Bm-MPKl/sfiI was ligated with Vector S/sfiI via a DNA ligation 
reaction using T4 ligase (New England Biolabs, NEB) and lOx ligase buffer (NEB) in a 
20 pi reaction, which was incubated overnight in a 16°C water bath. The insert to vector 
molar ratio was 5:1. A “No Insert control” tube was set up as a control. The ligation 
reaction (10 pi) was transformed into DH5a chemically competent E.Coli cells (70 pi) 
(Invitrogen). The transformation mixture was kept on ice for 30 min and was heat 
shocked at 37°C for 45 seconds. Immediately after this step, the transformation mixture 
was moved back to ice for 2 min. Then, 500 pi of SOC medium was added at room 
temperature. The transformation mixture was incubated at 37°C on a shaker (sideways) 
at 240 rpm for 1 h. Transformation mixture was plated onto pre-warmed LB agar plates 
containing 100 pg/mL ampicillin and incubated (upside down) overnight at 37°C.
From the LB plate, six single colonies assumed to contain the Bm- 
MPKl/pFASTBAC expression vector construct were inoculated separately in 2 mL of 
LB Broth with 100 pg/mL ampicillin in 15 mL conical centrifuge tubes. The cultures 
were incubated overnight in 37°C incubator with shaking at 240 rpm. The plasmid was 
purified using Plasmid DNA Purification Using the QIAprep Spin Miniprep Kit and a 
Microcentrifuge protocol (QIAGEN) as per manufacturer’s instructions. The Bm- 
MPKl/pFASTBAC expression vector DNA was eluted in 50 pi of EB buffer. The 
concentration of the purified DNAs was measured using a NanoDrop spectrophotometer
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(Thermo-Scientific, Wilmington, DE). Each purified vector DNA (8 pi) was digested 
with 1 pi of Sfil restriction enzyme and 10X Sure/Cut Buffer M in a 10 pi reaction which 
was incubated for 1 h in 50°C water bath. The reaction was run on 1.5% agarose gel in 
lx TAE buffer along with a ?ddindIII0X Haelll DNA marker (310-23,130 base pairs) to 
verify the correct Bm-MPKl ligation into the pFASTBAC plasmid.
II. Generation of a Recombinant Bm-MPKl/pFASTBAC-based Baculovirus
In order to generate recombinant Bm-MPKl/pFASTBAC-based Baculovirus, one 
plasmid construct (34.2 ng/pl) was transformed into the DHlOBac competent cells. 
These cells contain the bacmid with a mini-attTn7 target site and the helper plasmid (12). 
The helper plasmid provides the transposition proteins, which help the mini-Tn7 element 
on the pFASTBAC plasmid to transpose to the mini-attTn7 target site on the bacmid (12). 
Approximately 100 ng of Bm-MPKl/pFASTBAC expression vector DNA was added to 
50 pi of commercial high efficiency DHlOBac competent E.coli cells (Invitrogen). The 
transposition mixture was kept on ice for 30 min and moved to a 42°C water bath for 45 
seconds for heat-shock. Instantly, the transposition mixture was placed on ice and 900 pi 
of SOC medium was added after 2 min incubation. The tube was sealed with parafilm 
and placed in a 37°C incubator for 3-4 h on a shaker at 200-240 rpm for recovery. The 
transposition mixture was diluted 102 and 103 times after the 4 h incubation. From both 
diluted samples, 100 pi were plated onto pre-warmed LB plates containing 
KAN+GENT+TET+IPTG+X-GAL (standard LB with 50 pg/mL KAN, 10 pg/mL TET 
(in EtOH) and 7 pg/mL Gentamycin, 40 pg/mL IPTG, and 100 pg/mL Bluo-Gal) and
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incubated for 48 h at 37°C. Plates were subsequently transferred into the cold room to 
obtain a better blue-white color distinction. Ten recombinant white colonies were 
separately inoculated in 1 mL LB +KTG media into 1.5 mL eppendorf tubes. These 1 
mL cultures were grown overnight at 37°C on a shaker at 200-240 rpm (turning 
overhead). The Bm-MPKl/pFASTBAC-Baculovirus (BACMID DNA or recombinant 
bac virus) was purified using the Plasmid DNA Purification QIAprep Spin Miniprep Kit 
and a Microcentrifuge protocol (QIAGEN).
A two-step Polymerase Chain Reaction (initial denaturation step at 94°C for 6 
min; annealing at 94°C for 30 seconds followed by extension at 68°C for 6 min; 30 
cycles) was performed on purified recombinant bacmid DNA (from each of 10 isolates) 
to verify the correct transposition. The M13-F and M13-R primers were designed and 
synthesized at Hoffmann-La Roche. The sequence for M13-F (Forward Primer) is “ccc 
agt cac gac gtt gta aaa eg” and for M13-R (Reverse Primer) is “AGC GGA TAA CAA 
TTT CAC ACA GG”. The melting temperatures for forward and reverse primers were 
73°C and 70°C, respectively. For each reaction, 3 pi of purified bacmid DNA was mixed 
with 12.5 pi of Taq PCR Master Mix (QIAGEN), 7.5 pi distilled water, 1 pi forward 
primer, and 1 pi reverse primer in 200 pi PCR tubes. The PCR reactions were run on a 
1.5% agarose gel in lx TAE buffer to identify correctly transposed clones, where a 3.7 kb 
insert is expected (a 2.3 kb pFASTBAC-1 insert combined with cloned and transposed 
1.1 kb Bm-MPKl plus 0.3 kb GST tag). One positive clone was chosen to generate Bm- 
MPKl/pFASTBAC based Baculovirus DNA. The DNA from 25 mL culture was 
purified using the QIAprep Spin Miniprep Kit and a Microcentrifuge procedure
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(QIAGEN). Prior to purification, 3 mL of culture was used to prepare 1 mL aliquots of 
15% glycerol stocks for long term storage at -80°C. The lysate derived from the 25 mL 
culture was divided into four parts and run over four QIAprep spin columns. Each of the 
four columns was eluted in 50 pi EB buffer. The concentration of purified bacmid DNA 
was measured using the NanoDrop spectrophotometer.
For subsequent DNA purifications, the Bm-MPKl/pFASTBAC- Baculovirus cells 
were inoculated into 50 mL LB broth containing TKG and incubated overnight in a 37°C 
incubator with a rotator speed of 200-240 rpm. The DNA was purified using 
PureYield™ Plasmid Midiprep system as per manufacturer’s instructions (Promega). 
Three elutions were collected using 500 pi of nuclease free water. To again verify the 
presence of a 1.1 kb Bm-MPKl insert, an Sfil restriction enzyme digestion was 
performed on 1 pg of purified Bm-MPKl/pFASTBAC-Baculovirus DNA in 20 pi final 
volumes. The mixture was incubated at 50°C for 1 h and run on a 0.5% agarose gel 
parallel to undigested BACMID DNA, BACMID DNA from the previous QIAGEN prep 
and DNA markers.
III. Transfection of SF9 Insect cells with Bm-MPKl/pFASTBAC-based
Baculovirus Expression Vector
SF9 Insect cells (Invitrogen) were used for transfection with the Bm- 
MPKl/pFASTBAC-based Baculovirus expression vector to express Bm-MPKl. Cells 
were grown in suspension and were seeded at 0.8-1 x 106 cells/mL in SF-900-II SFM
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media (Gibco, Life Technologies) with 2% FCS plus lx penicillin/streptomycin. They 
were passaged every 2-3 days when the cell density reached 6-8 x 106 cells/mL with the 
cell viability being greater than 96%. Later in the study, media was substituted with SF- 
900-III SFM (Gibco by Life Technologies) due to changes in the manufacturer’s yeast 
extract component. Cells were grown at 27°C in a non-humidified environment with 
shaking at 120-140 rpm and maintained in 150 mL or 250 mL non-pyrogenic sterile 
plastic storage bottles (Coming Incorporated, Coming, NY) with tightly closed caps. The 
titer range from 1-8 x 106 cells/mL with a viability of 96-100% was used for experiments. 
The trypan blue exclusion method with manual hemocytometer cell counting was used to 
determine cell titers and viability.
Cells were split to 1 x 106 cells/mL 3-4 days before transfection and grown until 
the cell density reached 4-6 x 106 cells/mL. On the day of transfection, the cell density 
was 5 x 106 cells/mL with 99% cell viability. Using this culture, 1 x 106 cells (200 pi) 
per each 35 mm well in sterile 6 Well Cell Culture Cluster plate (Coming Incorporated, 
Coming, NY) were seeded in 2 mL SF-900-II SFM media containing 2% FCS and 0.5x 
pen/strep. Cells were incubated at 27°C for 1 h to allow attachment. To transfect two 
wells with Bm-MPKl/pFASTBAC-Baculovirus vector DNA, 2 pg of plasmid was 
diluted in SF-900-II SFM media without FCS to obtain a final volume of 200 pi. In a 
separate tube, 12 pi of Cellfectin 2000 (Invitrogen) was mixed with SF-900-II SFM 
without FCS in a final volume of 200 pi. The diluted plasmid DNA was transferred to 
the diluted Cellfectin to form the DNA- Cellfectin complexes. The contents were mixed 
gently by tapping the tube. In addition, 6 pi of Cellfectin 2000 was added into 100 pi of
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SF-900-II SFM without FCS, which was mixed with another 100 pi of SF-900-II media 
without FCS to represent the NO DNA control. These tubes were incubated at room 
temperature for 45 min. After incubation, SF-900-II SFM media without FCS was added 
to the DNA- Cellfectin mix and to the No DNA control to a final volume of 2 mL and 1 
mL, respectively.
After cells attached, media from each well was removed. Cells were washed 
gently with 2 mL of fresh SF-900-II media without FCS. Then, 1 mL of diluted 
Cellfectin-DNA complex mixture was added to two wells. The No DNA mixture was 
added into a third well. A GFP virus (2 x 109 PFU/mL stock) was added to two wells as a 
control. The GFP virus stock was diluted by adding 5 pi and 0.5 pi virus to 1000 pi of 
complete media to obtain an approximate MOI (multiplicity of infection) of 1 (200x) and 
0.1 (2000x), respectively. From these diluted samples, 100 pi for each sample was added 
onto another two wells. The plate was placed at 27°C for 4 h. The DNA- Cellfectin 
mixture and NO DNA mixture were removed from the wells after 4 h incubation and 
replaced with 2 mL of pre-warmed SF900-II SFM media with 2% FCS and lx pen/strep. 
The plate was placed back into the 27°C incubator for 72 h in a humidified container 
(plastic container with a few layers of water-saturated paper towels on the bottom). The 
sixth unused well was used as a reference well for healthy looking cells. After 72 h, 
transfected vs. un-transfected cells were observed under a microscope. The supernatant 
(media containing virus) from the two wells transfected with Bm-MPKl/pFASTBAC- 
baculovirus DNA was removed (3-4 mL) and pooled together into 15 mL conical 
centrifuge tube. The supernatant was sterile-filtered using 0.22 pm filter unit
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(MILLEX - GS, Millipore Corporation) for further virus amplification. The collected 4 
mL supernatant was considered passage 1 (PI) and stored at 4°C. Collected GFP 
transfected cells and no DNA-transfected cells were stored at 4°C.
To generate passage 2 (P2), 3.5 mL of virus from PI was added to 15 mL SF9 
cells at 2 x 106 cells/mL. Cells were grown at 27°C for 4 days. The cell density and cell 
viability were determined every 24 h. The cell viability decreased from 93.2% on day 1 
to 79.7% on day 4 (Figure 6). On day 4, 12 mL from P2 was added to 100 mL actively 
growing SF9 cells at 3 x 106 cells/mL to generate passage 3 (P3). Cells were grown at 
27°C for 3-4 days. When cell viability was 75-80%, the cells were spun at 4000 rpm for 
10 min. The supernatant (100 mL) was collected and transferred into a new bottle. FCS 
was added to obtain a final concentration of 10% to increase the virus stability for long­
term storage. Collected virus stock was stored at 4°C. The tubes were covered with 
aluminum foil to protect the virus from light.
IV. Bm-MPKl/pFASTBAC-Baculovirus Suspension culture Titration Assay
When baculovirus production processes in suspension culture are scaled up, 
titration of the viral stocks used is important to ensure reproducible infections via 
controlled MOIs. A suspension culture titration method was therefore used to measure 
Bm-MPKl/pFASTBAC-Baculovirus titer (5). In this method, cessation of cell growth is 
correlated to the viral titer used for cell infection. For this assay, 20 mL SF9 cell cultures 
at a known initial cell density (ICD) of 1 x 106 cells/mL were infected with different
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virus dilutions. Three cultures received 1 mL virus aliquots of 10, 104 and 106 fold 
diluted GFP standard virus (known initial titer = 2 x 109 pfu/mL). The Bm- 
MPKl/pFASTBAC-based Baculovirus was diluted at 103, 104, and 105 fold in SF-900 II 
SFM media with 2% FCS + 1% pen/strep in 5 mL blue-capped tubes. From each 
dilution, 1 mL diluted virus was added to three 20 mL cultures. The cells were incubated 
on a shaker (120 rpm) at 27°C for 3 days. The Peak Cell Density (PCD) values in each 
culture were determined by hemocytometer count after a 3 day culture period. Based on 
reference 5, the correlation between MOI and resulting cell densities was described as log 
PCD/ICD = -0.16 log MOI + 0.1. Using this equation and the standard GFP virus 
dilutions, a Bm-MPKl virus titer was estimated.
V. Infection of SF9 cells with Bm-MPKl/pFASTBAC-Baculovirus
V. a Determination o f virus dilution
One initial experiment was performed to determine the correct virus dilutions and 
cell harvest times for use with the Bm-MPKl/pFASTBAC-Baculovirus. For this 
purpose, 100 mL SF9 cells were grown to 3-4 x 106 cells/mL. In three 250 mL flasks, 
cells were then seeded at 2.5 x 106 cells/mL in SF-900-II SFM media with 2% FCS +1 
% pen/strep in a final volume of 40 mL. Subsequently, 4 mL, 400 pi and 40 pi of Bm- 
MPKl/pFASTBAC-Baculovirus were added to obtain final virus dilution of 10X in 
flask 1, 100X in flask 2, and 1000X in flasks 3, respectively. For the non-infected 
control, cells were seeded at 2.5 x 106 cells/mL in final volume of 20 mL. Cells in each
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of the four flasks were mixed well by pipetting. An aliquot was collected to determine 
the Initial Cell Density (ICD) value. All flasks were incubated at 27°C for 4 days on a 
shaker (120 rpm). The Trypan blue exclusion method with hemocytometer counting 
was used to obtain cell density and cell viability each day. From each flask, 5 mL 
aliquots were collected on days 2, 3, and 4 and the cells were spun out at 4000 rpm for 
10 min and saved for later analysis.
V. b SF9 cells Infection for production ofBm-MPKl protein
For Bm-MPKl production, 100 mL SF9 cells seeded at 2.5 x 106cells/mL in a 1L 
plastic bottle were infected with 10 mL of Bm-MPKl/pFASTBAC-Baculovirus to obtain 
10X final virus dilution. Cells were grown at 27°C for 3-4 days on the shaker until the 
cell viability dropped to 75-85%. Infected cells were harvested by spinning at 800 x g for 
5 min. Cell pellets were stored at -80°C for later analysis.
V c Stress Treatments o f the SF9 cells by Sodium arsenate. Copper sulfate, or Heat 
Shock
For all stress treatments, SF9 cells were first infected with Bm- 
MPKl/pFASTBAC-Baculovirus as stated in above section V.a. When the cell viability 
dropped to between 75-85%, cells were stressed by several different regimens. For the 
sodium arsenate and copper sulfate treatment, cells were stressed 4 h prior to harvests at a 
final concentration of 400 pM. For the heat shock treatment, cells were incubated at
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37°C and 43°C for 1 h and 4 h prior to harvesting the cells. Some infected cells were 
harvested prior to the stress treatments as control. As a further control, the same stresses 
were performed on uninfected SF9 cells. Afterwards, cultures were spun at 800 x g for 5 
min to collect the pellets.
V d Cell Lysis usins IPER®
The Insect cell pellets were washed twice with 10 mL of cold lx PBS (Phosphate 
Buffered Saline) and centrifuged at 800 x g for 5 min. The insect cells were lysed with 
1 mL of I-PER® (Insect Cell Protein Extraction Reagent; Thermo Scientific) with 1:100 
Halt™ Protease Inhibitor Cocktail (Thermo-Fisher Scientific) for every 5x 106- 2 x  107 
cells. Resuspended cells were incubated on ice for 10 min. The lysis solution was then 
centrifuged at 15,000 x g for 15 min at 4°C. The cell lysate was transferred into new 15 
mL conical centrifuge tubes.
VI. Purification of GST-tagged Bm-MPKl
GST-tagged Bm-MPKl from infected SF9 insect cells was purified using Thermo 
Scientific Pierce® Glutathione Agarose in a Gravity-Flow Column at 4°C. The column 
was packed with 16 mL of Pierce-Glutathione Agarose and equilibrated using 10 bed 
volumes of lx PBS. The equilibrated resin was removed from the column to mix with 
crude extract. The mixture was incubated for either 3 h or overnight on a rotator in the 
cold room. After, the mixture was loaded onto the column to collect flow through which
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was reloaded to allow for more complete binding. The resin was washed four times with 
5 mL lx PBS, followed by a fifth 5 mL wash with buffer containing 25 mM HEPES, 150 
mM NaCl or 500 mM NaCl, 1 mM DTT, 10% glycerol, and 1:100 Halt™ Protease 
Inhibitor Cocktail. Then, proteins were eluted in 50-100 mL of the above buffer with 
added 10 mM reduced L-glutathione (Sigma-Aldrich) by gravity flow. Protein 
concentrations in the different fractions were measured using the standard relation 1 
mg/ml = 1A280 with the NanoDrop spectrophotometer. In order to concentrate the 
proteins, eluted fractions were spun for 30-45 minutes at 4000 rpm using Amicon® 
Ultra-15 mL (30,000 Nominal Normal Weight Limit, [NMWL]) or 0.5 mL (10,000 
NMWL) Centrifugal Filters (Merck Milipore Ltd).
VII. Western Blot and SDS-PAGE of GST-Bm-MPKl protein
The GST-Bm-MPKl protein collected from Bm-MPKl/pFASTBAC-Baculovirus 
infected SF9 cells were analyzed by SDS-PAGE and Western blot. Gel samples were 
prepared in 20 pL volume using 65% of protein samples and 35% master-mix (25% 
NuPAGE SDS sample buffer (Invitrogen) and 10% of 500 mM DTT reducing agent). 
Samples were then placed in a 90°C heat block for 5 min. After the heating step, the 
samples were quickly spun using a tabletop centrifuge. Samples were loaded onto 10- 
well NuPAGE 4-12% Bis-Tris gel (Invitrogen) along with molecular weight markers; 
Novex sharp pre-stained protein standard (Invitrogen) for SDS-PAGE and MagicMark™ 
XP Western Standard (Invitrogen) for Western blots. Gels were run at 200-V for 40 min 
in cold MOPS SDS running buffer (Invitrogen). Gels were stained with staining solution
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(0.05% Coomasie Blue, 10% acetic acid and 44% methanol) for 1 h, fixed for 30 min in 
fixing solution (50% methanol and 10% acetic acid), and destained for 1 h in 5% acetic 
acid. Later in the study, gels were stained using a commercial reagent, InstantBlue™ 
(Expedeon).
For Western blots, proteins separated on gels were electro-transferred onto 
polyvinylidene fluoride (PVDF) membranes in NuPAGE transfer buffer (Invitrogen) 
using a TE77XP Semi-Dry Blotter (Hoefer, Holliston, MA) at 54 mA per blot for 1 h. 
Membranes were then placed into 5% non-fat dry milk (blocking solution) in TBS-T 
(Tris-buffered saline and 0.05% Tween® 20) for 1 h to block non-specific binding sites. 
Membranes were then incubated in primary antibody (1:1000 goat anti-GST polyclonal 
IgG antibody, GE Healthcare) diluted in 10 mL of TBS-T containing 10 mg BSA and 
0.01% sodium azide for 1 h at room temperature or overnight at 4°C. Membranes were 
washed three times with TBS-T buffer for 5 min before the 30 min incubation with 
alkaline phosphatase-coupled secondary antibody. The secondary antibody solution was 
prepared by adding 2 pi of mouse anti-goat IgG-AP, 1:5000 (Santa Cruz Biotechnology, 
Santa Cruz, CA) into 10 mL of TBS-T. The membranes were washed twice with TBS-T 
and once with distilled water for 5 min. Finally, they were developed using 2 mL of 
Western Blue® Stabilized Substrate for Alkaline Phosphatase (Promega). Water was 
used to terminate the reaction after bands became visible. Additional western blots were 
probed with a primary antibody specific for the phosphorylated kinase (phopho-p38 
rabbit polyclonal IgG antibody (1:2000, Santa Cruz Biotechnologies); Secondary
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antibody: alkaline phosphatase linked anti-rabbit IgG (1:2500, Promega)) to detect stress 
activated GST-Bm-MPKl protein from cells treated with arsenate, copper or heat.
VIII. IMAP assay
In order to measure the enzymatic activity of Bm-MPKl produced in SF9 cells, 
an IMAP FP (Immobilized metal ion affinity-based fluorescence polarization) assay 
(Molecular Devices) was performed using the manufacture’s procedures. The IMAP 
assay was initiated with the incubation of Bm-MPKl enzyme with fluorescent peptide 
substrate, FAM-p38tide (120 nM) in the presence of ATP (100 pM). The kinase reaction 
was incubated for 1 h to form phosphorylated fluorescent peptide product. Nanoparticles 
(1:1000 dilution) containing a coupled trivalent metal ion were added to the reaction. 
These nanoparticles bind to the phosphorylated peptide product decreasing the rotational 
speed of the peptide, resulting in a higher fluorescence polarization signal. The Bm- 
MPKl kinase activity was detected by high-affinity interactions of nanoparticles with 
phospho groups on either serines, threonines, or tyrosine. The assay was read using a 
Synergy 2 Microplate reader with an excitation wavelength of 485 nm and an emission 
wavelength of 528 nm.
IX. Activation of Bm-MPKl by upstream kinase MKK6
Purified Bm-MPKl was activated by 1 pi (0.30 pg/pl) of the p38 upstream kinase 
MKK6 in a 1 mL reaction containing 1 mM DTT, 10 pM ATP, 5X assay buffer and
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distilled water. In order to optimize the activation procedure three different volumes of 
Bm-MPKl were used, 50 pi, 100 pi and 250 pi. A negative control was performed for 
each condition without MKK6. The reactions were incubated at 30°C for 30 min. The 




In order to produce recombinant Bm-MPKl in SF9 cells, a synthetic open reading 
frame encoding Bm-MPKl was successfully subcloned into a pFASTBAC plasmid using 
DNA ligation and bacterial transformation. The purified plasmid DNAs from 
transformed colonies were digested with Sfil restriction enzyme and analyzed using DNA 
gel electrophoresis. The gel data showed two bands for each of six colonies analyzed 
(Figure 3). The higher molecular weight band migrating between 6557 and 4361 bp 
indicate pFASTBAC (~5kb) and the lower molecular weight bands between 1353 and 
1078 bp show the Bm-MPKl, 1.1 kb insert. This result verifies the successful Bm- 
MPKl ligation with the pFASTBAC vector. The concentrations of the purified plasmid 
DNA from six colonies were 25.6 ng/pl, 17.7 ng/pl, 34.2 ng/pl, 21.6 ng/pl, 18.0 ng/pl, 
and 20.6 ng/pl. The negative control plate did not yield any colonies.
The Bm-MPKl/pFASTBAC-based Baculovirus was successfully generated in 
DHlOBac competent cells via site-specific transposition (4, 12). The gel data (Figure 4) 
shows that 7 out of 10 colonies contain a 3.7 kb band verifying the correct generation of 
the recombinant Bm-MPKl /pFASTBAC recombinant bac virus (0.3 kb GST, 1.1 kb Bm- 
MPKl, and 2.3 kb pFASTBAC fragments totaling a 3.7 kb band as expected). Isolate #9 
(Figure 4, lane 10) was chosen for amplification and purification of bacmid DNA. Using 
the QIAGEN Miniprep kit, 28.075 ng/pl of bacmid DNA was obtained. Using Pure
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Yield™ Plasmid Midiprep system (Promega), a total of 141.63 pg of bacmid DNA 
(362.1 ng/pl, 210 ng/pl, and 155 ng/pl) was collected.
The bacmid DNAs from both preps were digested with Sfil and analyzed on 0.5% 
agarose gel parallel to undigested bacmid DNA (Figure 5). The bacmid DNA purified 
using the QIAGEN procedure was obtained at a very low yield only (lanes 2 and 6), 
making a meaningful analysis difficult. For the Promega prep DNA, Sfil digestion 
clearly showed the release of a correctly sized Bm-MPKl-insert at 1.1 kb (lane 3), further 
supporting the results from the PCR analysis shown in figure 4.
Expression and purification of recombinant Bm-MPKl
The protein kinase, Bm-MPKl was successfully expressed in Insect SF9 cells as a 
GST-tagged recombinant protein. The optimal virus dilution conditions for SF9 cell 
infection were determined by analyzing cells infected with 10X, 100X, and 1000X virus 
dilutions and harvested on days 2, 3 and 4. The western blot results show that at all three 
viral concentrations lead to similar expression levels of Bm-MPKl protein with the 
expected molecular weight 67 kDa (Bm-MPKl-40kDa + GST-tag, 27kDa) (Figure 7A). 
However, SDS-PAGE analysis shows that protein bands obtained after infection with a 
10X virus dilution are stronger compared to bands for the other two virus concentrations 
(Figure 7B). Since the recombinant Bm-MPKl virus titer was unknown prior to this 
experiment, 10-fold virus dilution and day 3 was used for further expression and 
harvesting. Later, a Bm-MPKl virus titer of about 2 x 109 pfu/mL was estimated using
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suspension culture titration assay. Using this titer, the actual MOI used for experiments 
was 4.
For purification of GST-Bm-MPKl protein, cell lysates from infected SF9 cells 
were purified using Thermo Scientific Pierce® Glutathione Agarose in a Gravity-Flow 
Column. The column fractions were analyzed by SDS-PAGE and Western blot showing 
the successful expression and purification of GST-tagged Bm-MPKl from SF9 cells 
(Figures 8A -8B). The purification procedure gave an about 95-99% pure protein 
preparation (Figure 8B). Recombinant Bm-MPKl was successfully expressed and 
purified under arsenate, copper, and heat stress conditions (Figure 9B).
Enzymatic activity of Bm-MPKl
The enzymatic activity of recombinant Bm-MPKl was evaluated using an 
Immobilized metal ion affinity based fluorescence polarization (IMAP) assay. Similar to 
the mammalian expression system, purified recombinant Bm-MPKl from infected but 
unstressed SF9 cells did not show any kinase activity. To determine if recombinant Bm- 
MPKl can be activated, infected SF9 cells were stressed with 400 pM sodium arsenate, 
400 pM copper sulfate, or heat shock treatments at 37°C and 43°C. I have demonstrated 
that sodium arsenate treatment leads to the activation of recombinant Bm-MPKl 
produced in infected SF9 cells (Figure 10). There was no activity for copper sulfate 
treatment, as the activity looks similar to unstressed Bm-MPKl. The heat shock 37°C 
treatment does not fully activate the recombinant Bm-MPKl from infected SF9 cells
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(Figure 10). The infected SF9 cells stressed at 43°C die (data not shown). In addition, 
the inactive recombinant Bm-MPKl was significantly activated using the upstream 
activator MKK6 (Figure 11).
A western blot was performed to confirm the activation of Bm-MPKl as 
evidenced by the dual phosphorylation of the highly conserved TGY active site. The blot 
analysis with the anti-phospho p38 antibody shows a 67 kDa band (Figure 9A) for each 
stress condition but with various intensities. The Bm-MPKl band intensity for Arsenate 
stress (9A-lane 7), and 37°C (9A- lane 5) heat shock is very strong indicating that the 
protein Bm-MPKl is phosphorylated at the TGY domain. The Bm-MPKl fractions 
collected from copper stressed SF9 cells results in a band pattern (9A- lane 8) similar to 
unstressed cells (9C-lane 4) indicating low or no phosphorylation. The same protein 
samples were run on a western and probed with anti-GST antibody showing two bands 
with various intensity for 37°C heat shock and sodium arsenate treatment. These 
findings indicate that about 90% and 60% of the kinase proteins are activated (higher 
band) for arsenate treatment and 37°C heat shock treatments, respectively. These results 
are also supported by the IMAP assay results.
Bm-MPKl protein yield
An excellent yield of recombinant Bm-MPKl was obtained with approximately 
3.25 mg of protein from a 100 mL culture. Recombinant Bm-MPKl was eluted in 100 
mL of elution buffer containing 25 mM HEPES, 10 mM reduced L-glutathione, 500 mM
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NaCl, 1 mM DTT, 10% glycerol, and 1:100 Halt™ Protease Inhibitor Cocktail by gravity 
flow. The protein concentration was 0.2 mg/mL in collected elutions. Proteins were 
concentrated approximately 15 fold. The concentration reading for concentrated elution 
(6.5 mL) was approximately 0.5 mg/mL.
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DISCUSSION
Previous work in our lab has demonstrated that Bm-MPKl can be inhibited by 
known p38 inhibitors compromising B. malayi anti-oxidative stress responses and leading 
to parasite death. In view of this, Bm-MPKl is a potential anti-parasitic drug target for 
the treatment of lymphatic filariasis and other filarial diseases. In order to fully exploit 
the potential of Bm-MPKl as a drug target, large quantities of Bm-MPKl are required 
for drug screening campaigns and structural determination. To achieve this goal, I have 
established the SF9 cell/Baculovirus expression system for high-level production of 
recombinant Bm-MPKl. illustrated a highly efficient SF9 cell/Baculovirus expression 
system for high-level production of recombinant Bm-MPKl.
The SF9 cell/Baculovirus expression vector system has many advantages 
compared to other eukaryotic systems such as the mammalian HEK 293-Freestyle cells 
for expressing heterologous proteins. The major advantage of the insect cell expression 
is that once Baculovirus containing an open reading frame infects SF9 cells and viral 
stocks are made, large quantities of SF9 cells can be grown and infected in one step. In 
contrast, mammalian expression systems such as HEK cells can only be transiently 
transfected with expression plasmids requiring time consuming plasmid preparation. The 
SF9 cell/Baculovirus system also generally produces much more recombinant protein 
than mammalian systems. Estimates have been made indicating that up to 30% of total 
SF9 cellular protein can be recombinant(4). My typical yields of Bm-MPKl using SF9 
cell/Baculovirus systems are ~400 pg per 20 mL culture, wheras for mammalian cell
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expression, a similar yield would require 100-300 mL of culture. Another advantage of 
BAC system is that insect cells provide a full complement of eukaryotic posttranslational 
modifications thereby combining high expression levels with protein modification 
capabilities clearly superior to E. Coli systems.
In summary, I have successfully cloned a synthetic Bm-MPKl open reading 
frame into a pFASTBAC vector and generated a Bm-MPKl/pFASTBAC-based 
Baculovirus via transposition. I have successfully expressed recombinant Bm-MPKl in 
SF9 insect cells. Bm-MPKl was successfully activated in cells by reactive oxygen 
species generated by sodium arsenate treatment and in vitro with the human upstream 
activator, MKK6. This expression system will be an important tool for producing high- 
























Figure 1: Nucleotide Sequence of SF9Bm-MPKl. The gene sequence was chemically 
synthesized at GenScript (Piscataway, NJ). The sequence is 1139 base pairs long and 
contains Sfil restriction enzyme sites at each end. The sequence for the 5’-end Sfll A site 
is GGCCTCAGCGGCCGCA (highlighted in yellow) and for the 3’-end Sfi B site is 
GGCCGGGTCGGCC (highlighted in green).
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Figure 2: Generation of recombinant baculoviruses and gene expression with the 
Bac-To-Bac expression system. This approach for generating a recombinant 
baculovirus uses site-specific transposition with Tn7 to insert foreign genes into bacmid 
DNA propagated in E. coli. The Bm-MPKl protein kinase ORF was cloned into a 
pFASTBAC vector to produce a Bm-MPKl/pFASTBAC plasmid vector, which was then 
transformed into DHlOBac competent cells. These cells contain the bacmid with a mini- 
attTn7 target site and the helper plasmid (12). The helper plasmid provides the 




Figure 3: DNA Gel Electrophoresis analysis of pFASTBAC plasmid containing a 
Bm-MPKl Insert. A,HindIII0X Haelll DNA markers (lane 1 & 8), Bm- 
MPK1/pFASTBAC plasmid construct (lanes 2-7) generated via DNA ligation and 
transformation. Plasmid DNA (7 pi) was added with loading dye (3 pi) and loaded on 
1.5% agarose gel in lx TAE buffer. EtBr was used to stain the gel. Black arrow 














Figure 4: Identification of correct transposition via DNA Gel Electrophoresis 
analysis: AHindIII0X Haelll DNA markers (lane 1 & 13), Bm-MPKl/pFASTBAC- 
based Baculovirus (lanes 2-11), No template DNA control (lane 12). This gel shows the 
analysis of the PCR products generated to demonstrate correct transposition, using BAC 
virus DNA from different isolates as template. Red arrow indicates 3.7 kb Bm- 














Figure 5: Verification of Bm-MPKl inserts in purified viral DNA isolates via Sfll 
restriction digestion: MdindlllOX Haelll DNA markers (lane 1 & 5), Bm- 
MPKl/pFASTB AC-based Baculovirus -  QIAGEN (Digested- lane 2, Undigested -  lane 
6), Bm-MPKl/pFASTB AC-based Baculovirus- PROMEGA (Digested- lane 3, 
Undigested -  lanes 7 & 8), BmJNK/pFASTBAC-based Baculovirus from another 
project- PROMEGA (Digested- lane 4, Undigested- lanes 9 & 10). Red arrow indicates 
the presence of 1.1 kb Bm-MPKl insert
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(A) (B)
Figure 6: Comparison between uninfected and infected SF9 cells. (A) Uninfected 
SF9 cells. (B) SF9 cells infected with Bm-MPKl/pFASTBAC-based Baculovirus, Day 3 
after infection. Cells were observed using a light microscope and phase contrast at a 
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Figure 7: Production of GST-Bm-MPKl from SF9 Insect cells. (A) Western Blot of 
GST-Bm-MPKl developed using anti-GST goal polyclonal IgG antibody (1: 1000). 
MagicMark™ XP Western Protein Standard (lane 1), lOx- Day 2 (lane 2), lOx- Day 3 
(lane 3), lOx -  Day 4 (lane 4), lOOx- Day 2 (lane 5), lOOx- Day 3 (lane 6), lOOx- Day 4 
(lane 7), lOOOx- Day 3 (lane 8), lOOOx- Day 4 (lane 9), and Negative Control (lane 10) 
(B)Coomasie Blue stained 4-12% Bis-Tris gel. lOx- Day 2 (lane 1), lOx- Day 3 (lane 2), 
lOx -  Day 4 (lane 3), lOOx- Day 2 (lane 4), lOOx- Day 3 (lane 5), lOOx- Day 4 (lane 6), 
lOOOx- Day 3 (lane 7), lOOOx- Day 4 (lane 8), Negative Control (lane 9), and Novex® 
Sharp Standard (lane 10)
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Figure 8: Purification of GST-Bm-MPKl from SF9 Insect cells. Molecular weight 
markers; MagicMark™ XP Western Protein Standard & Novex® Sharp Standard (lane 
1), Crude Extract (lane 2), Flow through #2 (lane 3), Wash 1 (lane 4), Wash 5 (lane 5), 
Eluent-1 (lane 6), Eluent-2 (lane 7), Eluent-3 (lane 8), Eluent-4 (lane 9), and Eluent-5 
(lane 10) [A] Western blot of GST-Bm-MPKl developed using anti-GST goat polyclonal 

























Figure 9 Dual Phosphorylation of Bm-MPKl in Crude Extracts. [A] Western blot 
developed using phopho-p38 rabbit polyclonal IgG antibody (1:2000, Santa Cruz 
Biotechnologies) [B] Western blot developed using anti-GST goat polyclonal IgG 
antibody (1:1000). MagicMark™ XP Western Protein Standard (lane 1), Bm-MPKl 
from mammalian cells- Positive Control (lane 2), Uninfected SF9 cells-Negative Control 
(lane 3), Infected SF9 cells/Inactivated Bm-MPKl (lane 4), activated Bm-MPKl at 37°C 
(lane 5), activated Bm-MPKl at 43°C (lane 6), activated Bm-MPKl with 400 pM 
Arsenate (lane 7), activated Bm-MPKl with pM Copper sulfate(lane 8), Uninfected SF9 
cells stressed with 400 pM Arsenate (lane 9), and Uninfected SF9 cells stressed with 400 
pM Copper sulfate. Each stress treatment was performed for 4 hours with a buffer 
containing 500 mM NaCl.
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Figure 10: Enzymatic activity of recombinant Bm-MPKl using IMAP assay: The
recombinant Bm-MPKl from infected SF9 cells was activated by stressing the cells with 
various treatments 4 hours prior to harvest. The blue diamonds represent unstressed Bm- 
MPKl. Purple X represent activated Bm-MPKl by 400 pM copper sulfate. Red squares 
represent Bm-MPKl activated by 37°C heat shock. Green triangles represent activated 
Bm-MPKl by 400 pM sodium arsenate. The assay was read using a Synergy 2 
Microplate reader with an excitation wavelength of 485 nm and an emission wavelength 
of 528 nm.
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Figure 11: Activation of recombinant Bm-MPKl using MKK6: Purified Bm-MPKl 
was incubated with 0.30 jag of p38 upstream kinase MKK6 in a 1 mL reaction with 1 mM 
DTT, 10 pM ATP, 5X assay buffer and distilled water. The reaction was incubated for 30 
minutes at 27°C. The reaction (10 pi) was serially diluted to check the activity using 
IMAP assay. The activity was read at an excitation wavelength of 485 nm and an 
emission wavelength of 528 nm. Blue diamonds represent inactive Bm-MPKl. Red 
square represents activated Bm-MPKl by MKK6.
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